AtheroMed
Date | Investors | Amount | Round |
---|---|---|---|
$6.0m | Series A | ||
N/A | $2.4m | Debt | |
N/A | $7.5m | Debt | |
$13.0m | - | ||
$6.0m | Debt | ||
N/A | $4.3m | Debt | |
$117m Valuation: $117m | Acquisition | ||
Total Funding | $19.0m |
Recent News about AtheroMed
EditAtheroMed Inc. specializes in developing innovative medical devices aimed at treating peripheral artery disease (PAD), a condition characterized by narrowed arteries reducing blood flow to the limbs. The company's flagship product, the Phoenix Atherectomy System, is designed to remove plaque from blood vessels, thereby improving blood flow and reducing the risk of complications such as limb amputation. AtheroMed serves healthcare providers, including hospitals and specialized clinics, operating primarily in the medical device market. The business model revolves around the sale and distribution of its proprietary devices, generating revenue through direct sales and partnerships with medical institutions. The company leverages advanced technology to offer effective and minimally invasive solutions, positioning itself as a leader in the PAD treatment space.
Keywords: peripheral artery disease, medical devices, atherectomy, plaque removal, blood flow, healthcare providers, hospitals, clinics, advanced technology, minimally invasive.